Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition.
about
Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Combination of two anti-tubuli ...... nchymal-epithelial transition.
@en
Combination of two anti-tubuli ...... nchymal-epithelial transition.
@nl
type
label
Combination of two anti-tubuli ...... nchymal-epithelial transition.
@en
Combination of two anti-tubuli ...... nchymal-epithelial transition.
@nl
prefLabel
Combination of two anti-tubuli ...... nchymal-epithelial transition.
@en
Combination of two anti-tubuli ...... nchymal-epithelial transition.
@nl
P2860
P356
P1433
P1476
Combination of two anti-tubuli ...... nchymal-epithelial transition.
@en
P2093
Ken-Ichi Ito
Takaaki Oba
P2860
P304
22986-23002
P356
10.18632/ONCOTARGET.25184
P407
P577
2018-05-01T00:00:00Z